RxDoctor Payments Data

Michael Holyoak, DO

Endocrinology, Diabetes & Metabolism · Meridian, IDNPI 1679968051

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $1,412 of the $2,205 with a category attached, or 64.0%. Amgen accounts for 66.2% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2021 at $1,529 and has fallen 93.1% since, to $105 in 2025.

$2,205in general payments, 2019–2025

Across 26 payments — averaging $84.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • Tandem Diabetes Care, Inc.$353
  • Ascendis Pharma Endocrinology Inc$125
  • Abbott$71
  • Insulet Corporation$46
  • Medtronic$34
  • plus $115 from 6 others

What the payments were for

  • Speaking & faculty fees$1,41264%
  • Food & beverage$79336%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few endocrinology, diabetes & metabolism providers in Idahoto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$29,590
Medicare patients
203
Services billed
365

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StrensiqAsfotase Alfa26$1,219,611
MounjaroTirzepatide77$101,055
TymlosAbaloparatide29$75,671
Repatha SureclickEvolocumab51$41,367
TrulicityDulaglutide34$39,215
JardianceEmpagliflozin25$35,070
OzempicSemaglutide24$29,543
GenotropinSomatropin13$22,277
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog15$21,212
NexletolBempedoic Acid14$17,308
BaqsimiGlucagon31$15,894
Tresiba Flextouch U-100Insulin Degludec12$10,580
Humalog Kwikpen U-100Insulin Lispro15$9,675
Cabergoline21$8,772
NovologInsulin Aspart23$8,007

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Baqsimi, Insulin Lispro$33$158,718158 claims
Novo NordiskOzempic, Novolog$23$37,55147 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few endocrinology, diabetes & metabolism providers in Idahoon file to place this against a meaningful peer group, so we don't.

Other endocrinology, diabetes & metabolism in Meridian

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →